# US 11,998,600 B2 · Enhancing the therapeutic activity of an immune checkpoint inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,600 B2
- Document ID: US11998600B2
- Status: Granted
- Kind: B2
- Application number: 17/110,543
- Filed: 2020-12-03
- Published: 2021-04-08
- Granted: 2024-06-04
- Earliest claimed: 2015-06-01
- Assignees: MaineHealth
- Applicants: MaineHealth
- Inventors: Peter C. Brooks; Jennifer M. Caron; Liangru Contois
- Web page: https://patentgrep.com/patent/US11998600B2

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C07K 16/18: against material from animals or humans
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.

## Claims

### Claim 1

A method of treating cancer in a subject comprising,
identifying a subject that has been diagnosed with cancer;
administering an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor comprises a PD-1 antibody; and
administering an antagonist of denatured collagen or an antigen-binding fragment thereof, wherein the antagonist of denatured collagen comprises an antagonist of the XL313 cryptic collagen epitope, wherein the antagonist comprises the XL313 monoclonal antibody deposited with ATCC accession number PTA-6552, wherein the XL313 monoclonal antibody binds a cryptic RGDKGE (SEQ ID NO. 1) containing collagen epitope, and
thereby treating cancer in said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antagonist of denatured collagen or an antigen-binding fragment thereof enhances anti-tumor activity of the immune checkpoint inhibitor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group comprising of melanoma, central nervous system (CNS) cancer, CNS germ cell tumor, lung cancer, leukemia, multiple myeloma, renal cancer, malignant glioma, medulloblastoma, breast cancer, ovarian cancer, prostate cancer, bladder cancer, fibrosarcoma, pancreatic cancer, gastric cancer, head and neck cancer, colorectal cancer, a cancer cell derived from a solid cancer or hematological cancer, wherein the hematological cancer is a leukemia or a lymphoma, wherein the leukemia is acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic myelogenous leukemia (CML) or acute monocytic leukemia (AMoL), or wherein the lymphoma is follicular lymphoma, Hodgkin's lymphoma, or Non-Hodgkin's lymphoma, wherein the Hodgkin's lymphoma is Nodular sclerosing subtype, mixed-cellularity subtype, lymphocyte-rich subtype, or lymphocyte depleted subtype; wherein the cancer is a solid cancer comprising melanoma.

### Claim 5 (depends on 1)

The method of claim 1, wherein said immune checkpoint inhibitor is administered at a dose of 0.01-10 mg/kg bodyweight, and wherein said antagonist of collagen is administered at a dose of 0.01-25 mg/kg bodyweight.

### Claim 6 (depends on 1)

The method of claim 1, wherein said composition is administered once per hour, or wherein said composition is administered once every two weeks for 4 to 6 weeks.
